Top

Gepubliceerd in:

2013 | OriginalPaper | Hoofdstuk

24. Stable Angina

Auteurs : Sachin Mehta, MD, Neal Kleiman, MD, FACC

Uitgeverij: Springer New York

Abstract

In the USA, it is estimated that there are more than 13 million people with coronary artery disease (CAD). Beyond a thorough history and physical, there are several diagnostic tests used to detect CAD. If indicated, medications with different mechanistic behaviors are used to prevent cardiac injury and provide symptomatic relief. In addition to medical therapy, revascularization plays a significant function in treatment. The roles of coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) have evolved over the past several decades. The decision to pursue revascularization and the type of procedure to perform depends on the amount of ischemic burden. Additionally, if a patient continues to have symptoms despite optimal medical therapy, revascularization should be considered. Finally, exercise is a key component in treating CAD. Every patient should be instructed to perform exercise training to supplement medical therapy and revascularization procedures for optimal treatment.

vorige hoofdstuk Risk Factors and Prevention, Including Hyperlipidemia

volgende hoofdstuk Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes)

Thom T et al. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85–151.PubMed

Georgeson S et al. Acute cardiac ischemia in patients with syncope: importance of the initial electrocardiogram. J Gen Intern Med. 1992;7(4):379–86.PubMed

Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.PubMed

Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–44.PubMed

Folsom AR, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2002;144:233–8.PubMed

Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.PubMed

Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–81.PubMed

Leonard DA, Merhige ME, Williams BA, et al. Elevated expression of the interleukin-8 receptors CXCR1 and CXCR2 in peripheral blood cells in obstructive coronary artery disease. Coron Artery Dis. 2011;22(7):491–6.PubMed

Schunkert H, König IR, Kathiresan S. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333–8.PubMed

10.

Wang Y, Zheng Y, Zheng W, et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007;50(8):760–7.PubMed

11.

Shiffman D, Rowland CM, Sninsky JJ, et al. Polymorphisms associated with coronary heart disease: better by the score. Curr Opin Mol Ther. 2006;8(6):493–9.PubMed

12.

Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44(7):1429–35.PubMed

13.

Ohashi K, Ouchi N, Kihara S, et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004;43(7):1195–200.PubMed

14.

Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004;110(15):2132–6.PubMed

15.

Roberts R, Stewart AF. 9p21 and the genetic revolution for coronary artery disease. Clin Chem. 2012;58(1):104–12.PubMed

16.

International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103–9.

17.

Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease: a meta-analysis. Circulation. 1989;80:87–98.PubMed

18.

Campeau L. Grading of angina pectoris. Circulation. 1976;54:522–3.PubMed

19.

Bourque JM, Charlton GT, Holland BH, et al. Prognosis in patients achieving ≥10 METS on exercise stress testing: was SPECT imaging useful? J Nucl Cardiol. 2011;18(2):230–7.PubMed

20.

Kaul S, Boucher CA, Newell JB, et al. Determination of the quantitative thallium imaging variables that optimize detection of coronary artery disease. J Am Coll Cardiol. 1986;7:527.PubMed

21.

Husain Z, Palani G, Cabrera R, et al. Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging. 2011;28(7):1841–9.PubMed

22.

Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54(13):1123–30.PubMed

23.

Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol. 2012;19(1):126–41.PubMed

24.

Gibbons RJ, Fyke FE, Clements IP, et al. Noninvasive identification of severe coronary artery disease using exercise radionuclide angiography. J Am Coll Cardiol. 1988;11:28.PubMed

25.

Quinones MA, Verani MS, Haichin RM, et al. Exercise echocardiography versus T1-201 single photon emission computerized tomography in evaluation of coronary artery disease: analysis of 292 patients. Circulation. 1992;85:1026–31.PubMed

26.

FAA. Coronary artery disease. 2012. http://www.faa.gov/licenses_certificates/medical_certification/specialissuance/coronary. Last accessed 10 May 2012.

27.

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Clinical trials. 2012. http://clinicaltrials.gov/ct2/show/NCT01471522. Last accessed 10 May 2012.

28.

Maron DJ, Stone GW, Berman DS, et al. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. Am Heart J. 2011;162(6):1034–43.PubMed

29.

Galbraith JE, Murphy ML, Desoyza N. Coronary angiogram interpretation: interobserver variability. JAMA. 1981;240:2053–9.

30.

Grodin CM, Dydra I, Pastgernac A, et al. Discrepancies between cineangiographic and post-mortem findings in patients with coronary artery disease and recent myocardial revascularization. Circulation. 1974;49:703–9.

31.

Lowe HC, Narula J, Fujimoto JG, et al. Intracoronary optical diagnostics current status, limitations, and potential. JACC Cardiovasc Interv. 2011;4(12):1257–70.PubMed

32.

Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenosis. N Engl J Med. 1996;34:1703–8.

33.

Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995;92(11):3183–93.PubMed

34.

Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213–24.PubMed

35.

Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56(3):177–84.PubMed

36.

Iskandrian AS, Chae SC, Heo J, et al. Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease. J Am Coll Cardiol. 1993;22:665–70.PubMed

37.

Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death. Circulation. 1998;97:535–43.PubMed

38.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged anti platelet therapy in various categories of patients. Br Med J. 1994;308:81–98.

39.

Topol EJ, Easton D, Harrington RA, BRAVO Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399–406.PubMed

40.

Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–5.PubMed

41.

Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.PubMed

42.

Conley PB, Delaney SM. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in throm- bosis. Curr Opin Hematol. 2003;10:333–8.PubMed

43.

Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340–5.PubMed

44.

Cannon CP, CAPRIE Investigators. Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Am J Cardiol. 2002;90:760–2.PubMed

45.

Steinhubl SR, Berger PB, Mann III JT, et al. Clopidogrel for the reduction of events during observation. JAMA. 2002;288:2411–20.PubMed

46.

CURE Trial Investigators. Clopidogrel in unstable angina to prevent recurrent events. N Engl J Med. 2001;345:494–502.

47.

Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.PubMed

48.

Abrams J. Third North American conference on nitroglycerine therapy. Am J Cardiol. 1992;70:1B–103.

49.

Cheitlin MD, Hutter Jr AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease: ACC/AHA expert consensus document. Circulation. 1999;99:168–77.PubMed

50.

Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855–60.PubMed

51.

The BHAT Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. The beta-blocker heart attack trial. JAMA. 1982;247:1707–14.

52.

The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J. 1985;6:199–211.

53.

The ISIS-1 Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;ii:57–66.

54.

Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107–14.PubMed

55.

Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739–45.PubMed

56.

Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356:1949–54.PubMed

57.

The MDPIT Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–92.

58.

The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol. 1990;66:779–85.

59.

Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462.PubMed

60.

Chaitman BR, Pepine CJ, Parker J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309.PubMed

61.

Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566.PubMed

62.

Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375.PubMed

63.

The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–7.

64.

The Air Force/Texas Coronary Atherosclerosis Prevention Research Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–22.

65.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

66.

The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.

67.

ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.

68.

Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.

69.

Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE-IT). N Engl J Med. 2004;350:1495–504.PubMed

70.

Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227–39.PubMed

71.

Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. Circulation. 1998;97:1029–36.PubMed

72.

Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004;93:307–12.PubMed

73.

McKenney JM, McCormick LS, Weiss S, et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998;104:137–43.PubMed

74.

Investigators WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women—principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.

75.

The Heart and Estrogen/progestin Replacement Study (HERS) Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–13.

76.

The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199–208.

77.

Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062–71.PubMed

78.

Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37.PubMed

79.

Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. N Engl J Med. 1991;325:756.PubMed

80.

Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.PubMed

81.

Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha-tocopherol and beta-carotene supplements on symptoms, progression, and prognosis in angina pectoris. Heart. 1998;79:454–8.PubMed

82.

Stephens NG, Parsons A, Schofiled PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.PubMed

83.

GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet. 1999;354:447–55.

84.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145–53.

85.

Barnard RJ, MacAlpin R, Kattus AA, et al. Effect on training on myocardial oxygen supply/demand balance. Circulation. 1977;56(2):289.PubMed

86.

Dressendorfer RH, Smith JL, Amsterdam EA, et al. Reduction of submaximal exercise myocardial oxygen demand post-walk training program in coronary patients due to improved physical work efficiency. Am Heart J. 1982;103(3):358.PubMed

87.

Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109(11):1371.PubMed

88.

Walther C, Möbius-Winkler S, Linke A, et al. Regular exercise training compared with percutaneous intervention leads to a reduction of inflammatory markers and cardiovascular events in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2008;15(1):107–12.PubMed

89.

Onishi T, Shimada K, Sato H, et al. Effects of phase III cardiac rehabilitation on mortality and cardiovascular events in elderly patients with stable coronary artery disease. Circ J. 2010;74(4):709–14.PubMed

90.

Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682.PubMed

91.

Soga Y, Yokoi H, Amemiya K, et al. Safety and efficacy of exercise training after coronary stenting in patients with stable coronary artery disease. Circ J. 2011;75(10):2379–86.PubMed

92.

Yoshikawa D, Ishii H, Kurebayashi N, et al. Association of cardiorespiratory fitness with characteristics of coronary plaque: assessment using integrated backscatter intravascular ultrasound and optical coherence tomography. Int J Cardiol. 2011;162(2):123–8.PubMed

93.

Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–71.PubMed

94.

Fernández-Ortiz J, Badimon J, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562–9.PubMed

95.

Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation. 1964;30:654–70.PubMed

96.

King III SB. Angioplasty from bench to bedside to bench. Circulation. 1996;93:1621–9.PubMed

97.

Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58(1):19–25.PubMed

98.

The EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–96.

99.

The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92.

100.

The SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coro- nary artery. N Engl J Med. 2003;349:1315–23.

101.

Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate- release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–94.PubMed

102.

RAVEL Study Group. Randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.

103.

Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527.PubMed

104.

Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.PubMed

105.

McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–21.PubMed

106.

Kuntz RE, Baim DS. Defining coronary restenosis. Circulation. 1993;88:1310.PubMed

107.

Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J. 2000;21(21):1739.PubMed

108.

Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30(6):1428.PubMed

109.

Goldberg SL, Loussararian A, De Gregorio J, et al. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol. 2001;37(4):1019.PubMed

110.

Elliott JM, Berdan LG, Holmes DR, et al. One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (CAVEAT I). Circulation. 1995;91:2158.PubMed

111.

Baim DS, Cutlip DE, Sharma SK, et al. Final results of the balloon versus optimal atherectomy trial. Circulation. 1998;97:322–31.PubMed

112.

Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. 1997;96:91–8.PubMed

113.

Semenza GL, Agani F, Iyer N, et al. Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest. 1998;114:40S–5.PubMed

114.

Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342:626–33.PubMed

115.

Shyu KG, Wang MT, Wang BW, et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hy- brid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res. 2002;54:576–83.PubMed

116.

Isner JM. Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis. Am J Cardiol. 1998;10A:63S–4.

117.

Goncalves LM. Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev Port Cardiol. 1998;17(2s):II11–20.PubMed

118.

Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114–23.PubMed

119.

Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation. 1998;97:645–50.PubMed

120.

Grines CL, Watkins MW, Mahmarian JJ, AngiogeneGENe Therapy (AGENT-2) Study Group, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42(8):1339.PubMed

121.

Van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009;301(19):1997.PubMed

122.

Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361(9351):47.PubMed

123.

Fuchs S, Satler LF, Kornowsk R, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol. 2003;41(10):1721.PubMed

124.

Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004;110(11 Suppl 1):II213.PubMed

125.

Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107(18):2294.PubMed

126.

Garrett HE, Dennis EW, DeBakey ME, et al. Aortocoronary bypass with saphenous vein graft: seven-year follow-up. JAMA. 1973;223:792–4.PubMed

127.

Favaloro RG. Bilateral internal mammary artery implants: operative technique: a preliminary report. Cleve Clin Q. 1967;34:61–6.PubMed

128.

Favaloro RG. Landmarks in the development of coronary artery bypass surgery. Circulation. 1998;98:466–78.PubMed

129.

Cameron AAC, Davis KB, Rogers WJ, et al. Recurrence of angina after coronary bypass surgery. Predictors and prognosis (CASS registry). J Am Coll Cardiol. 1995;26:895–9.PubMed

130.

Borger MA, Cohen G, Buth KJ, et al. Multiple arterial grafts. Radial versus right internal thoracic arteries. Circulation. 1998;98:II-7–14.

131.

Fletcher GF, Balady G, Froelicher VF, et al. Exercise standards: a statement for health professionals from the American Heart Association Writing Group. Circulation. 1995;91:580–615.PubMed

132.

Parisi AF, Folland ED, Hartigan P. Angioplasty compared to medicine. N Engl J Med. 1992;326:10–6.PubMed

133.

RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the second Randomized Intervention Treatment of Angina (RITA-2) trial. Lancet. 1997;350:461–8.

134.

Yusuf S, Zucker D, Pedruzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10- year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–70.PubMed

135.

BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.

136.

Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503.PubMed

137.

Shaw L, Berman D, Maron D, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.PubMed

138.

The BARI (Bypass Angioplasty Revascularization Investigation) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multi-vessel disease. N Engl J Med. 1996;335:217–25.

139.

Abizaid A, Costa MA, Centemero M, Arterial Revascularization Therapy Study Group, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104:553–8.

140.

Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961.PubMed

141.

Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219.PubMed

142.

Morice MC, Serruys PW, Kappetein A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121(24):2645–53.PubMed

143.

Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364(18):1718–27.PubMed

Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319–25.PubMed

Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165–7.PubMed

Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203.PubMed

Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591–602.PubMed

Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920–59.PubMed

Titel: Stable Angina
Auteurs: Sachin Mehta, MD
Neal Kleiman, MD, FACC
Uitgeverij: Springer New York
Boek: Essential Cardiology
Print ISBN: 978-1-4614-6704-5

Elektronisch ISBN: 978-1-4614-6705-2

Copyright: 2013
DOI: https://doi.org/10.1007/978-1-4614-6705-2_24

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen